Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003131 · ClinicalTrials.gov registry record · Phase 2
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00003131 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 55 participants.
The verdict
NCT00003131, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid leukemia in first relapse.
Interventions
- DRUG chemotherapy
- DRUG gemtuzumab ozogamicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 1997-02 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003131
The ClinicalTrials.gov registry entry for NCT00003131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.
NCT00003131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003131 about?
NCT00003131 is a clinical study titled "CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid leukemia in first relapse.
What is the current status of trial NCT00003131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 1997-02. Estimated completion is 2002-02.
What interventions are being tested in trial NCT00003131?
The interventions under investigation include: chemotherapy (DRUG), gemtuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00003131?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.